Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca2+ responses in endothelial cells

British Journal of Pharmacology

Volumn 154, Issue 1, 2008, Pages 82-92

  Campos Toimil, M ^a   Keravis, T ^b   Orallo, F ^a   Takeda, K ^b   Lugnier, C ^b,c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CNRS   (France)

Author keywords

Calcium; cAMP; Endothelial; Human primary cell; PDE4; Rolipram

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUCLADESINE; CALCIUM ION; CYCLIC AMP; CYCLOHEXIMIDE; FURA 2; HISTAMINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IVA; PHOSPHODIESTERASE IVB; ROLIPRAM; THROMBIN;

ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; HYPERTENSION; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOENZYMATIC ASSAY; UMBILICAL VEIN; WESTERN BLOTTING;

EID: 42949156735     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.56     Document Type: Article

References (55)

1. Bender AT, Beavo JA (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488–520.
2. Bolz SS, Pohl U (1997). Indomethacin enhances endothelial NO release—evidence for a role of PGI 2 in the autocrine control of calcium‐dependent autacoid production. Cardiovasc Res 36: 437–444.
3. Bregestovski P, Bakhramov A, Danilov S, Moldobaeva A, Takeda K (1988). Histamine‐induced inward currents in cultured endothelial cells from human umbilical vein. Br J Pharmacol 95: 429–436.
4. Bruce JI, Straub SV, Yule DI (2003). Crosstalk between cAMP and Ca 2+ signaling in non‐excitable cells. Cell Calcium 34: 431–444.
5. Bugrim AE (1999). Regulation of Ca 2+ release by cAMP‐dependent protein kinase. A mechanism for agonist‐specific calcium signaling ? Cell Calcium 25: 219–226.
6. Burden RL, Faires JD (2005). Numerical differentiation and integration. In: Burden RL, Faires JD (eds). Numerical Analysis, 8th edn. Thomson/Brooks Cole: Belmont, CA, pp 167–248.
7. Campos‐Toimil M, Lugnier C, Droy‐Lefaix MT, Takeda K (2000). Inhibition of type 4 phosphodiesterase by rolipram and Ginkgo biloba extract (EGb 761) decreases agonist‐induced rises in internal calcium in human endothelial cells. Arterioscler Thromb Vasc Biol 20: E34–E40.
8. Carson MR, Shasby SS, Shasby DM (1989). Histamine and inositol phosphate accumulation in endothelium: cAMP and a G protein. Am J Physiol 257: L259–L264.
9. Carter TD, Hallam TJ, Cusack NJ, Pearson JD (1988). Regulation of P2y‐purinoceptor‐mediated prostacyclin release from human endothelial cells by cytoplasmic calcium concentration. Br J Pharmacol 95: 1181–1190.
10. Challiss RA, Adams D, Mistry R, Nicholson CD (1998). Modulation of spasmogen‐stimulated Ins(1,4,5)P 3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. Br J Pharmacol 124: 47–54.
11. Chomczynski P, Sacchi N (1987). Single‐step method of RNA isolation by acid guanidinium thiocyanate‐ phenol‐chloroform extraction. Anal Biochem 162: 156–159.
12. Duchêne AD, Takeda K (1997). P2Y‐ and P2U‐mediated increases in internal calcium in single bovine aortic endothelial cells in primary culture. Endothelium 5: 277–286.
13. Favot L, Keravis T, Holl V, Le Bec A, Lugnier C (2003). VEGF‐induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90: 334–343.
14. Favot L, Keravis T, Lugnier C (2004). Modulation of VEGF‐induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 92: 634–645.
15. Hallam TJ, Jacob R, Merritt JE (1988). Evidence that agonists stimulate bivalent‐cation influx into human endothelial cells. Biochem J 255: 179–184.
16. Hippenstiel S, Witzenrath M, Schmeck B, Hocke A, Krisp M, Krull M et al. (2002). Adrenomedullin reduces endothelial hyperpermeability. Circ Res 91: 618–625.
17. Hopkins NK, Gorman RR (1981). Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. J Clin Invest 67: 540–546.
18. Hosokawa M, Sato A, Ishigamori H, Kohno H, Tanaka T, Takahashi K (2001). Synergistic effects of highly unsaturated fatty acid‐containing phosphatidyl‐ethanolamine on differentiation of human leukemia HL‐60 cells by dibutyryl cyclic adenosine monophosphate. Jpn J Cancer Res 92: 666–672.
19. Houslay MD, Baillie GS, Maurice DH (2007). cAMP‐Specific phosphodiesterase‐4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100: 950–966.
20. Huston E, Gall I, Houslay TM, Houslay MD (2006). Helix‐1 of the cAMP‐specific phosphodiesterase PDE4A1 regulates its phospholipase‐D‐dependent redistribution in response to release of Ca 2+. J Cell Sci 119: 3799–3810.
21. Jin SL, Bushnik T, Lan L, Conti M (1998). Subcellular localization of rolipram‐sensitive, cAMP‐specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene. J Biol Chem 273: 19672–19678.
22. Keravis T, Silva AP, Favot L, Lugnier C (2007). Role of PDEs in vascular health and disease: endothelial PDEs and angiogenesis. In: Beavo JA, Francis SH, Houslay MD (eds). Cyclic Nucleotide Phosphodiesterases in Health and Diseases. CRC Press: Boca Raton, FL, pp 417–439.
23. Keravis T, Thaseldar‐Roumié R, Lugnier C (2005). Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. In: Lugnier C (ed). Phosphodiesterase Methods and Protocols. Methods in Molecular Biology Vol 307. Humana Press: Totowa, NJ, pp 63–74.
24. Keravis T, Wells JN, Hardman JG (1980). Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim Biophys Acta 613: 116–129.
25. Keularts IM, Van Gorp RM, Feijge MA, Vuist WM, Heemskerk JW (2000). Alpha(2A)‐adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels. J Biol Chem 275: 1763–1772.
26. Klein‐Soyer C, Beretz A, Millon‐Collard R, Abecassis J, Cazenave JP (1986). A simple in vitro model of mechanical injury of confluent cultured endothelial cells to study quantitatively the repair process. Thromb Haemost 56: 232–235.
27. Lamas M, Sassone‐Corsi P (1997). The dynamics of the transcriptional response to cyclic adenosine 3′,5′‐monophosphate: recurrent inducibility and refractory phase. Mol Endocrinol 11: 1415–1424.
28. Lantoine F, Iouzalen L, Devynck MA, Millanvoye‐Van Brussel E, David‐Dufilho M (1998). Nitric oxide production in human endothelial cells stimulated by histamine requires Ca 2+ influx. Biochem J 330: 695–699.
29. Lehrach H, Diamond D, Wozney JM, Boedtker H (1977). RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination. Biochemistry 16: 4743–4751.
30. Lin S, Fagan KA, Li KX, Shaul PW, Cooper DM, Rodman DM (2000). Sustained endothelial nitric‐oxide synthase activation requires capacitative Ca 2+ entry. J Biol Chem 275: 17979–17985.
31. Liu H, Maurice DH (1999). Phosphorylation‐mediated activation and translocation of the cyclic AMP‐ specific phosphodiesterase PDE4D3 by cyclic AMP‐dependent protein kinase and mitogen‐activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274: 10557–10565.
32. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC et al. (2000). Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP‐dependent protein kinase and mitogen‐activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275: 26615–26624.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275.
34. Lugnier C (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366–398.
35. Lugnier C, Keravis T, Le Bec A, Pauvert O, Proteau S, Rousseau E (1999). Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472: 431–446.
36. Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E (1993). Characterization of indolidan‐ and rolipram‐sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 265: 1142–1151.
37. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC (1986). Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35: 1743–1751.
38. Lugnier C, Stierle A, Beretz A, Schoeffter P, Lebec A, Wermuth CG et al. (1983). Tissue and substrate specificity of inhibition by alkoxy‐aryl‐lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity. Biochem Biophys Res Commun 113: 954–959.
39. Lynch JW, Lemos VS, Bucher B, Stoclet JC, Takeda K (1994). A pertussis toxin‐insensitive calcium influx mediated by neuropeptide Y2 receptors in a human neuroblastoma cell line. J Biol Chem 269: 8226–8233.
40. Maurice DH (1998). Cyclic nucleotide‐mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP. Cell Biochem Biophys 29: 35–47.
41. McGee SL, Hargreaves M (2008). AMPK and transcriptional regulation. Front Biosci 13: 3022–3033.
42. Mehats C, Tanguy G, Dallot E, Robert B, Rebourcet R, Ferre F et al. (1999). Selective up‐regulation of phosphodiesterase‐4 cyclic adenosine 3′,5′‐ monophosphate (cAMP)‐specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology 140: 3228–3237.
43. Nilius B, Droogmans G (2001). Ion channels and their functional role in vascular endothelium. Physiol Rev 81: 1415–1459.
44. Oike M, Droogmans G, Nilius B (1994). Amplitude modulation of Ca 2+ signals induced by histamine in human endothelial cells. Biochim Biophys Acta 1222: 287–291.
45. Okruhlicova L, Tribulova N, Eckly A, Lugnier C, Slezak J (1996). Cytochemical distribution of cyclic AMP‐dependent 3′,5′‐nucleotide phosphodiesterase in the rat myocardium. Histochem J 28: 165–172.
46. Rose RJ, Liu H, Palmer D, Maurice DH (1997). Cyclic AMP‐mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 122: 233–240.
47. Schwabe U, Miyake M, Ohga Y, Daly JW (1976). 4‐(3‐Cyclopentyloxy‐4‐methoxyphenyl)‐2‐pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′, 5′‐monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12: 900–910.
48. Sette C, Iona S, Conti M (1994). The short‐term activation of a rolipram‐sensitive, cAMP‐specific phosphodiesterase by thyroid‐stimulating hormone in thyroid FRTL‐5 cells is mediated by a cAMP‐dependent phosphorylation. J Biol Chem 269: 9245–9252.
49. Socorro L, Alexander RW, Griendling KK (1990). Cholera toxin modulation of angiotensin II‐stimulated inositol phosphate production in cultured vascular smooth muscle cells. Biochem J 265: 799–807.
50. Swinnen JV, Joseph DR, Conti M (1989). Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci USA 86: 5325–5329.
51. Tilley DG, Maurice DH (2002). Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 62: 497–506.
52. Tiruppathi C, Ahmmed GU, Vogel SM, Malik AB (2006). Ca 2+ signaling, TRP channels, and endothelial permeability. Microcirculation 13: 693–708.
53. Vischer UM, Wollheim CB (1998). Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca 2+ and cyclic adenosine monophosphate‐ dependent signaling in endothelial exocytosis. Blood 91: 118–127.
54. Von Der Weid PY, Serebryakov VN, Orallo F, Bergmann C, Snetkov VA, Takeda K (1993). Effects of ATP on cultured smooth muscle cells from rat aorta. Br J Pharmacol 108: 638–645.
55. Zhu B, Kelly J, Vemavarapu L, Thompson WJ, Strada SJ (2004). Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells. Biochem Pharmacol 68: 479–491.